PMID- 37455659
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240409
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 214
IP  - 1
DP  - 2023 Dec 11
TI  - Yeast beta-glucan modulates macrophages and improves antitumor NK-cell responses in 
      cancer.
PG  - 50-60
LID - 10.1093/cei/uxad080 [doi]
AB  - As the largest proportion of myeloid immune cells in tumors, macrophages play an 
      important role in tumor growth and regression according to their different 
      phenotypes, thus reprogramming macrophages has become a new research direction 
      for cancer immunotherapy. Yeast-derived whole beta-glucan particles (WGPs) can 
      induce M0 macrophages to differentiate into M1 macrophages and convert M2 
      macrophages and tumor-associated macrophages (TAMs) into M1 macrophages. In 
      vitro, studies have confirmed that WGP-treated macrophages increase the 
      activating receptors in natural killer cells (NK cells) and enhance the 
      cytotoxicity of NK cells. The extracellular regulated protein kinases (ERK) 
      signaling pathway is involved in WGP-mediated regulation of the macrophage 
      phenotype. Further in vivo studies show that oral WGP can significantly delay 
      tumor growth, which is related to the increased proportion of macrophages and NK 
      cells, the macrophage phenotype reversal, and the enhancement of NK cell immune 
      function. NK-cell depletion reduces the therapeutic efficacy of WGP in 
      tumor-bearing mice. These findings revealed that in addition to T cells, NK cells 
      also participate in the antitumor process of WGP. It was confirmed that WGP 
      regulates the macrophage phenotype to regulate NK-cell function.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      British Society for Immunology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Zhu, Zhichao
AU  - Zhu Z
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
FAU - He, Liuyang
AU  - He L
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
FAU - Bai, Yu
AU  - Bai Y
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
FAU - Xia, Lei
AU  - Xia L
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
FAU - Sun, Xiao
AU  - Sun X
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
FAU - Qi, Chunjian
AU  - Qi C
AUID- ORCID: 0000-0001-9567-112X
AD  - Laboratory of Oncology, Medical Research Center, The Affiliated Changzhou Second 
      People's Hospital of Nanjing Medical University, Changzhou, China.
LA  - eng
GR  - 32270954/National Natural Science Foundation of China/
GR  - ZD2022035/Jiangsu Provincial Health Commission/
GR  - CJ 20210095/Changzhou Sci & Tech Program/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (beta-Glucans)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Saccharomyces cerevisiae
MH  - *beta-Glucans/pharmacology/metabolism
MH  - Macrophages
MH  - *Neoplasms
MH  - Killer Cells, Natural
MH  - Immunity
PMC - PMC10711352
OTO - NOTNLM
OT  - NK cells
OT  - antitumor immunity
OT  - macrophages
OT  - whole glucan particle (WGP)
COIS- The authors have no competing interests.
EDAT- 2023/07/17 06:42
MHDA- 2023/12/17 09:44
PMCR- 2024/07/17
CRDT- 2023/07/17 04:04
PHST- 2023/01/03 00:00 [received]
PHST- 2023/05/24 00:00 [revised]
PHST- 2023/07/14 00:00 [accepted]
PHST- 2024/07/17 00:00 [pmc-release]
PHST- 2023/12/17 09:44 [medline]
PHST- 2023/07/17 06:42 [pubmed]
PHST- 2023/07/17 04:04 [entrez]
AID - 7225115 [pii]
AID - uxad080 [pii]
AID - 10.1093/cei/uxad080 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2023 Dec 11;214(1):50-60. doi: 10.1093/cei/uxad080.